© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Clinical Pearls: